<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>NSAIDs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i60.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i60.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i60.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i56.htm">Analgesics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i59.htm" title="Previous: Paracetamol">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1053.htm" title="Next: Dexibuprofen">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i60">NSAIDs</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>NSAIDs</b>
          has the following interaction information:
        </p><div><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i2.htm" name="_2">ACE Inhibitors</a></td><td>increased risk of renal impairment when  NSAIDs given with ACE inhibitors , also hypotensive effect antagonised</td><td></td></tr><tr><td><a href="41001i15.htm" name="_15">Adrenergic Neurone Blockers</a></td><td> NSAIDs antagonise hypotensive effect of adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i1099.htm" name="_1099">Aliskiren</a></td><td> NSAIDs possibly antagonise hypotensive effect of aliskiren </td><td></td></tr><tr><td><a href="41001i26.htm" name="_26">Alpha-blockers</a></td><td> NSAIDs antagonise hypotensive effect of alpha-blockers </td><td></td></tr><tr><td><a href="41001i107.htm" name="_107">Angiotensin-II Receptor Antagonists</a></td><td>increased risk of renal impairment when  NSAIDs given with angiotensin-II receptor antagonists , also hypotensive effect antagonised</td><td></td></tr><tr><td><a href="41001i232.htm" name="_232">Antidepressants, SSRI</a></td><td class="cBV"><b>increased risk of bleeding when  NSAIDs given with SSRIs </b></td><td></td></tr><tr><td><a href="41001i361.htm" name="_361">Aspirin</a></td><td class="cBV"><b>avoid concomitant use of  NSAIDs with aspirin (increased side-effects)</b></td><td></td></tr><tr><td><a href="41001i617.htm" name="_617">Baclofen</a></td><td> NSAIDs possibly reduce excretion of baclofen (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i440.htm" name="_440">Beta-blockers</a></td><td> NSAIDs antagonise hypotensive effect of beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i466.htm" name="_466">Calcium-channel Blockers</a></td><td> NSAIDs antagonise hypotensive effect of calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i478.htm" name="_478">Cardiac Glycosides</a></td><td> NSAIDs possibly increase plasma concentration of cardiac glycosides , also possible exacerbation of heart failure and reduction of renal function</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  NSAIDs given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i482.htm" name="_482">Clonidine</a></td><td> NSAIDs antagonise hypotensive effect of clonidine </td><td></td></tr><tr><td><a href="41001i865.htm" name="_865">Clopidogrel</a></td><td>increased risk of bleeding when  NSAIDs given with clopidogrel </td><td></td></tr><tr><td><a href="41001i484.htm" name="_484">Corticosteroids</a></td><td>increased risk of gastro-intestinal bleeding and ulceration when  NSAIDs given with corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td class="cBV"><b> NSAIDs possibly enhance anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm" name="_1120">Dabigatran Etexilate</a></td><td class="cBV"><b>possible increased risk of bleeding when  NSAIDs given with dabigatran etexilate </b></td><td></td></tr><tr><td><a href="41001i522.htm" name="_522">Diazoxide</a></td><td> NSAIDs antagonise hypotensive effect of diazoxide </td><td></td></tr><tr><td><a href="41001i524.htm" name="_524">Diuretics</a></td><td>risk of nephrotoxicity of  NSAIDs increased by diuretics , also antagonism of diuretic effect</td><td></td></tr><tr><td><a href="41001i544.htm" name="_544">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td>possible increased risk of hyperkalaemia when  NSAIDs given with potassium-sparing diuretics and aldosterone antagonists </td><td></td></tr><tr><td><a href="41001i1048.htm" name="_1048">Erlotinib</a></td><td class="cBV"><b>increased risk of bleeding when  NSAIDs given with erlotinib </b></td><td></td></tr><tr><td><a href="41001i224.htm" name="_224">Heparins</a></td><td>possible increased risk of bleeding when  NSAIDs given with heparins </td><td></td></tr><tr><td><a href="41001i763.htm" name="_763">Hydralazine</a></td><td> NSAIDs antagonise hypotensive effect of hydralazine </td><td></td></tr><tr><td><a href="41001i1015.htm" name="_1015">Iloprost</a></td><td>increased risk of bleeding when  NSAIDs given with iloprost </td><td></td></tr><tr><td><a href="41001i72.htm" name="_72">Ketorolac</a></td><td class="cBV"><b>avoid concomitant use of  NSAIDs with ketorolac (increased side-effects and haemorrhage)</b></td><td></td></tr><tr><td><a href="41001i372.htm" name="_372">Lithium</a></td><td class="cBV"><b> NSAIDs reduce excretion of lithium (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i511.htm" name="_511">Methotrexate</a></td><td class="cBV"><b> NSAIDs probably reduce excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i611.htm" name="_611">Methyldopa</a></td><td> NSAIDs antagonise hypotensive effect of methyldopa </td><td></td></tr><tr><td><a href="41001i1173.htm" name="_1173">Mifamurtide</a></td><td>avoidance of high doses of  NSAIDs advised by manufacturer of mifamurtide </td><td></td></tr><tr><td><a href="41001i764.htm" name="_764">Minoxidil</a></td><td> NSAIDs antagonise hypotensive effect of minoxidil </td><td></td></tr><tr><td><a href="41001i615.htm" name="_615">Moxonidine</a></td><td> NSAIDs antagonise hypotensive effect of moxonidine </td><td></td></tr><tr><td><a href="41001i631.htm" name="_631">Nitrates</a></td><td> NSAIDs antagonise hypotensive effect of nitrates </td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>avoid concomitant use of  NSAIDs with NSAIDs (increased side-effects)</b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i658.htm">Penicillamine</a></td><td>possible increased risk of nephrotoxicity when  NSAIDs given with penicillamine </td><td></td></tr><tr><td><a href="41001i826.htm">Pentoxifylline</a></td><td>possible increased risk of bleeding when  NSAIDs given with pentoxifylline </td><td></td></tr><tr><td><a href="41001i223.htm" name="_223">Phenindione</a></td><td class="cBV"><b> NSAIDs possibly enhance anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i1110.htm" name="_1110">Potassium Canrenoate</a></td><td> NSAIDs possibly antagonise diuretic effect of potassium canrenoate </td><td></td></tr><tr><td><a href="41001i1146.htm">Prasugrel</a></td><td>possible increased risk of bleeding when  NSAIDs given with prasugrel </td><td></td></tr><tr><td><a href="41001i193.htm">Quinolones</a></td><td class="cBV"><b>possible increased risk of convulsions when  NSAIDs given with quinolones </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  NSAIDs possibly increased by ritonavir </td><td></td></tr><tr><td><a href="41001i765.htm" name="_765">Sodium Nitroprusside</a></td><td> NSAIDs antagonise hypotensive effect of sodium nitroprusside </td><td></td></tr><tr><td><a href="41001i268.htm" name="_268">Sulfonylureas</a></td><td class="cBV"><b> NSAIDs possibly enhance effects of sulfonylureas </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td>possible increased risk of nephrotoxicity when  NSAIDs given with tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td class="cBV"><b>increased risk of bleeding when  NSAIDs given with venlafaxine </b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td>increased risk of haematological toxicity when  NSAIDs given with zidovudine </td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p>NSAIDs belongs to <b>Analgesics</b>
          but <b>Analgesics</b>
          has no interactions information.
        </p><p><b>Dexibuprofen</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p><p><b>Parecoxib</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  parecoxib increased by fluconazole (reduce dose of parecoxib)</td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr></tbody></table><p><b>Etoricoxib</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i638.htm">Ethinylestradiol</a></td><td> etoricoxib increases plasma concentration of ethinylestradiol </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  etoricoxib reduced by rifampicin </td><td></td></tr></tbody></table><p><b>Aceclofenac</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p><p><b>Acemetacin</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p><p><b>Celecoxib</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  celecoxib increased by fluconazole (halve dose of celecoxib)</td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  celecoxib reduced by rifampicin </td><td></td></tr></tbody></table><p><b>Dexketoprofen</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  dexketoprofen reduced by probenecid (increased plasma concentration)</b></td><td></td></tr></tbody></table><p><b>Diclofenac</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i219.htm">Anticoagulants</a></td><td class="cBV"><b>increased risk of haemorrhage when <i>intravenous</i>  diclofenac given with anticoagulants (avoid concomitant use, including low-dose heparins)</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of  diclofenac increased by ciclosporin (halve dose of diclofenac)</b></td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> diclofenac reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  diclofenac reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td>plasma concentration of  diclofenac increased by voriconazole </td><td></td></tr></tbody></table><p><b>Etodolac</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p><p><b>Fenoprofen</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p><p><b>Flurbiprofen</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  flurbiprofen increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr></tbody></table><p><b>Ibuprofen</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i361.htm">Aspirin</a></td><td> ibuprofen possibly reduces antiplatelet effect of aspirin </td><td></td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td> ibuprofen reduces excretion of baclofen (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  ibuprofen increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> ibuprofen reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  ibuprofen given with tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td>plasma concentration of  ibuprofen increased by voriconazole </td><td></td></tr></tbody></table><p><b>Indometacin</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i129.htm">Amikacin</a></td><td> indometacin possibly increases plasma concentration of amikacin in neonates</td><td></td></tr><tr><td><a href="41001i795.htm">Desmopressin</a></td><td> indometacin enhances effects of desmopressin </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td> indometacin antagonises effects of diuretics </td><td></td></tr><tr><td><a href="41001i544.htm">Diuretics, Potassium-sparing and Aldosterone Antagonists</a></td><td>increased risk of hyperkalaemia when  indometacin given with potassium-sparing diuretics and aldosterone antagonists </td><td></td></tr><tr><td><a href="41001i131.htm">Gentamicin</a></td><td> indometacin possibly increases plasma concentration of gentamicin in neonates</td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td>possible severe drowsiness when  indometacin given with haloperidol </td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> indometacin reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  indometacin reduced by probenecid (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i546.htm">Triamterene</a></td><td class="cBV"><b>occasional reports of reduced renal function when  indometacin given with triamterene—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Ketoprofen</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> ketoprofen reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  ketoprofen reduced by probenecid (increased plasma concentration)</b></td><td></td></tr></tbody></table><p><b>Ketorolac</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i219.htm">Anticoagulants</a></td><td class="cBV"><b>increased risk of haemorrhage when  ketorolac given with anticoagulants (avoid concomitant use, including low-dose heparins)</b></td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td> ketorolac antagonises effects of diuretics </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td class="cBV"><b> ketorolac reduces excretion of lithium (increased risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>avoid concomitant use of  ketorolac with NSAIDs (increased side-effects and haemorrhage)</b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i826.htm">Pentoxifylline</a></td><td class="cBV"><b>increased risk of bleeding  when  ketorolac given with pentoxifylline (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  ketorolac reduced by probenecid (increased plasma concentration)—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Mefenamic Acid</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p><p><b>Meloxicam</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i592.htm">Colestyramine</a></td><td>excretion of  meloxicam increased by colestyramine </td><td>Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> meloxicam reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr></tbody></table><p><b>Nabumetone</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p><p><b>Naproxen</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b> naproxen reduces excretion of methotrexate (increased risk of toxicity)—but for concomitant use in rheumatic disease see <a title="target-block: methotrexate cautions 10.1.3" href="5305.htm#_5305.1">Methotrexate, section 10.1.3</a></b></td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td class="cBV"><b>excretion of  naproxen reduced by probenecid (increased plasma concentration)</b></td><td></td></tr></tbody></table><p><b>Piroxicam</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  piroxicam increased by ritonavir (risk of toxicity)—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Sulindac</b> belongs to
      <b>NSAIDs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i1130.htm">Dimethyl sulfoxide</a></td><td class="cBV"><b>avoid concomitant use of  sulindac with dimethyl sulfoxide </b></td><td></td></tr></tbody></table><p><b>Tenoxicam</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p><p><b>Tiaprofenic Acid</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p><p><b>Tolfenamic Acid</b> belongs to
      <b>NSAIDs</b>
          but has no specific interaction information.
        </p></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1053.htm" title="Dexibuprofen">Dexibuprofen</a></li><li><a href="41001i961.htm" title="Parecoxib">Parecoxib</a></li><li><a href="41001i960.htm" title="Etoricoxib">Etoricoxib</a></li><li><a href="41001i61.htm" title="Aceclofenac">Aceclofenac</a></li><li><a href="41001i62.htm" title="Acemetacin">Acemetacin</a></li><li><a href="41001i898.htm" title="Celecoxib">Celecoxib</a></li><li><a href="41001i878.htm" title="Dexketoprofen">Dexketoprofen</a></li><li><a href="41001i64.htm" title="Diclofenac">Diclofenac</a></li><li><a href="41001i66.htm" title="Etodolac">Etodolac</a></li><li><a href="41001i68.htm" title="Fenoprofen">Fenoprofen</a></li><li><a href="41001i69.htm" title="Flurbiprofen">Flurbiprofen</a></li><li><a href="41001i783.htm" title="Ibuprofen">Ibuprofen</a></li><li><a href="41001i70.htm" title="Indometacin">Indometacin</a></li><li><a href="41001i71.htm" title="Ketoprofen">Ketoprofen</a></li><li><a href="41001i72.htm" title="Ketorolac">Ketorolac</a></li><li><a href="41001i73.htm" title="Mefenamic Acid">Mefenamic Acid</a></li><li><a href="41001i74.htm" title="Meloxicam">Meloxicam</a></li><li><a href="41001i75.htm" title="Nabumetone">Nabumetone</a></li><li><a href="41001i76.htm" title="Naproxen">Naproxen</a></li><li><a href="41001i78.htm" title="Piroxicam">Piroxicam</a></li><li><a href="41001i79.htm" title="Sulindac">Sulindac</a></li><li><a href="41001i80.htm" title="Tenoxicam">Tenoxicam</a></li><li><a href="41001i81.htm" title="Tiaprofenic Acid">Tiaprofenic Acid</a></li><li><a href="41001i83.htm" title="Tolfenamic Acid">Tolfenamic Acid</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i59.htm">Previous: Paracetamol</a> | <a class="top" href="41001i60.htm#">Top</a> | <a accesskey="]" href="41001i1053.htm">Next: Dexibuprofen</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>